Study completed in 2020
15 volunteers from surgeries of different EpCAM positive carcinomas,
Parameters measured in the intraoperative blood and ECs:
-EpCAM positive tumor cells
-Study was successfully completed
-No residual EpCAM positive Tumor Cells were found after use of Catuvab®.
Results demonstrate the efficacy and safety of CATUVAB®
Publication in preparation